Legal Representation
Attorney
Andrew N. Spivak
USPTO Deadlines
Next Deadline
488 days remaining
Section 8 Declaration Due (Principal Register) (Based on registration date 20210504)
Due Date
May 04, 2027
Grace Period Ends
November 04, 2027
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
22 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| May 4, 2021 | R.PR | A | REGISTERED-PRINCIPAL REGISTER | Loading... |
| Feb 16, 2021 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Feb 16, 2021 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Jan 27, 2021 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Aug 27, 2020 | FIXD | O | ELECTRONIC RECORD REVIEW COMPLETE | Loading... |
| Aug 21, 2020 | ERRR | O | ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED | Loading... |
| Aug 20, 2020 | CNSA | O | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Aug 20, 2020 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Aug 20, 2020 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Aug 17, 2020 | ALIE | A | ASSIGNED TO LIE | Loading... |
| Jul 29, 2020 | ERSI | I | TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED | Loading... |
| Jul 24, 2020 | GNS3 | O | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | Loading... |
| Jul 24, 2020 | GNSL | S | LETTER OF SUSPENSION E-MAILED | Loading... |
| Jul 24, 2020 | CNSL | R | SUSPENSION LETTER WRITTEN | Loading... |
| Jul 20, 2020 | XAEC | I | EXAMINER'S AMENDMENT ENTERED | Loading... |
| Jul 20, 2020 | GNEN | O | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | Loading... |
| Jul 20, 2020 | GNEA | F | EXAMINERS AMENDMENT E-MAILED | Loading... |
| Jul 20, 2020 | CNEA | R | EXAMINERS AMENDMENT -WRITTEN | Loading... |
| Jul 17, 2020 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| May 7, 2020 | MDSC | E | NOTICE OF DESIGN SEARCH CODE E-MAILED | Loading... |
| May 6, 2020 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Apr 28, 2020 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
Pharmaceutical preparations and substances for the treatment of cancer; Pharmaceutical preparations and substances for the prevention of cancer
Class 042
Research and development services in the field of antibodies; research and development services in the field of antibody technology; laboratory research and analysis services relating to the production of antibodies; scientific and technological services, namely, scientific research, analysis, and testing in the field of antibodies, and research and design relating thereto; industrial analysis and research services in the field of antibodies
Additional Information
Design Mark
The mark consists of the stylized, capitalized, purple word "OMBLASTYS" with three stacked V-shapes emanating from the top of the letter "Y", with the first in purple, the second in light green, and the third in teal. Centered beneath the word "OMBLASTYS", in all lower-case letters, in a different font, and in parentheses, is the word "OMBURTAMAB" in gray.
Color Claim
The color(s) teal, purple, light green, and gray is/are claimed as a feature of the mark.
Classification
International Classes
005
042
Disclaimers
The following terms have been disclaimed and are not claimed as part of the trademark:
Specific Disclaimer
"OMBURTAMAB"